CSL secured FDA approval for its factor XIIa-targeted garadacimab (Andembry) for prophylactic treatment of hereditary angioedema (HAE). The first-in-class monoclonal antibody provides a once-monthly preventative option for patients.

Gain free access to this article, as well as selected content from this journal and more on nature.com

or